---
title: "Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285373727.md"
description: "Aptevo has reported an 87% clinical benefit and 81% remission rate in 31 evaluable frontline AML patients through Cohort 5, significantly outperforming benchmarks. The RAINIER study is on track for completion in 2026, with plans for Phase 2 dose selection."
datetime: "2026-05-06T04:05:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285373727.md)
  - [en](https://longbridge.com/en/news/285373727.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285373727.md)
---

# Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock News

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock News

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Aptevo targets solid tumors with planned Nectin-4 x PD-L1 dual-targeting platform strategy](https://longbridge.com/en/news/293969770.md)
- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md)
- [Aptevo Therapeutics posts investor presentation on multispecific immunotherapies for cancer, led by mipletamig in AML](https://longbridge.com/en/news/290859040.md)